Trevi Therapeutics (TRVI) Q3 2026 Earnings Call Transcript
Cash runway now reaches 2030 as key trial timelines come into focus.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Global equities to rely on earnings growth as investor risk appetite weakens: Goldman Sachs
Goldman Sachs maintained an overweight stance on bonds, particularly longer-duration government securities.
Clearway Energy (CWEN) Q3 2026 Earnings Call Transcript
Clearway lifts 2027 cash flow outlook and sets 2031 per-share targets.
Paysign (PAYS) Q3 2026 Earnings Call Transcript
Patient programs drove margin gains, but a plasma client's departure looms in Q4.
Xenon (XENE) Q3 2026 Earnings Call Transcript
Xenon's NDA filing and pain drug data point to a busy stretch ahead.
Malaysia's October palm oil stocks hit new peak as output surges
KUALA LUMPUR: Malaysia’s palm oil stocks reached a new peak in October, after another record month of output more than offset the rebound in exports, data from the industry regulator showed on…
2027 interest rate risks, falling loan approvals cloud housing outlook: JLL Malaysia
KUALA LUMPUR: Malaysia's residential property market could face mounting pressure in 2027 as declining housing loan approval rates, tighter lending practices and the prospect of higher borrowing costs…